Anti-CD20 monoclonal antibodies in multiple sclerosis

References

• Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3–13.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl E. B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol. 2014;36(3):339–350.
   PubMed Web of Science ®Google Scholar
• Faissner S, Nikolayczik J, Chan A, et al. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. J Neurol. 2016;263(6):1092–1098.
   PubMed Web of Science ®Google Scholar
• Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294–300.
   PubMed Web of Science ®Google Scholar
• Kappos L, Hartung HP, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13(4):353–363.
   PubMed Web of Science ®Google Scholar
• Beauchemin P, Carruthers R. MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult Scler. 2016;22(2):254–256.
   PubMed Web of Science ®Google Scholar
• Sato H, Kabayashi D, Abe A, et al. Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report. BMC Res Notes. 2014;7:641.
   PubMedGoogle Scholar
• Hauser S, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase II, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing remitting multiple sclerosis: a phase II study. Neurology. 2014;82(7):573–581.
   PubMed Web of Science ®Google Scholar
• Piątosa B, Wolska-Kuśnierz B, Pac M, et al. B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood. Cytometry. 2010;78B:372–381.
   Google Scholar
• Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol. 2010;28:185–210.
   PubMed Web of Science ®Google Scholar
• Yuseff MI, Pierobon P, Reversat A, et al. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol. 2013;13(7):475–486.
   PubMed Web of Science ®Google Scholar
• Seifert M, Küppers R. Human memory B cells. Leukemia. 2016 Aug 26. doi:10.1038/leu.2016.226. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1):S3.
   PubMed Web of Science ®Google Scholar
• Stolp J, Turka LA, Wood KJ. B cells with immune-regulating function in transplantation. Nat Rev Nephrol. 2014;10(7):389–397.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944–950.
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–370.
   PubMed Web of Science ®Google Scholar
• Kessel A, Haj T, Peri R, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11(9):670–677.
   PubMed Web of Science ®Google Scholar
• Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest. 1942;21(5):571–577.
   PubMedGoogle Scholar
• Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59(4):555–559.
   PubMed Web of Science ®Google Scholar
• Willis SN, Stathopoulos P, Chastre A, et al. Investigating the antigen specificity of multiple sclerosis central nervous system-derived immunoglobulins. Front Immunol. 2015;6:600.
   PubMed Web of Science ®Google Scholar
• Disanto G, Morahan JM, Barnett MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology. 2012;78(11):823–832.
   PubMed Web of Science ®Google Scholar
• Von Büdingen HC, Tanuma N, Villoslada P, et al. Immune responses against the myelin oligodendrocyte glycoprotein in experimentalautoimmune demyelination. J Clin Immunol. 2001;21(3):155–170.
   PubMed Web of Science ®Google Scholar
• Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein. PNAS. 2006;103(50):19057–19062.
   PubMed Web of Science ®Google Scholar
• Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006;59:880–892.
   PubMed Web of Science ®Google Scholar
• Hottenrott T, Dersch R, Berger B, et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015;12:27.
   PubMedGoogle Scholar
• Jarius S, Eichhorn P, Jacobi C, et al. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280(1–2):98–100.
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128:1667–1676.
   PubMed Web of Science ®Google Scholar
• Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain. 2001;124:2169–2176.
   PubMed Web of Science ®Google Scholar
• Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain. 2012;135(6):1819–1833.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Bruck W, Parisi JE, et al. Heterogenity of multiple sclerosis lesions: implication for the pathogenesis of demyelination. Ann Neurol. 2001;47:707–717.
   Web of Science ®Google Scholar
• Barnett MH, Parratt JD, Cho ES, et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32–46.
   PubMed Web of Science ®Google Scholar
• Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210(13):2921–2937.
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod´homme T, Patarroyo JC, et al. B cell activation influences T cell polarization and outcome of anti-CD20 B cell depletion in CNS autoimmunity. Ann Neurol. 2010;68(3):369–383.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol. 2005;238(2):67–75.
   PubMed Web of Science ®Google Scholar
• Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. 2010;40:2942–2956.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Jensen J, Ryder LP, et al. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J Neuroimmunol. 1998;84:179–187.
   PubMed Web of Science ®Google Scholar
• Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing Bcell subsets: a comprehensive review. J Autoimmun. 2014;55:10e23.
   Web of Science ®Google Scholar
• Ma N, Xing C, Xiao H. BAFF suppresses IL-15 expresion in B cells. J Immunol. 2014;192(9):4192–4201.
   PubMed Web of Science ®Google Scholar
• Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008;105(26):9041–9046.
   PubMed Web of Science ®Google Scholar
• Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5):1001–1010.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452–461.
   PubMed Web of Science ®Google Scholar
• Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123:2737–2741.
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–6099.
   PubMed Web of Science ®Google Scholar
• Gomez-Nicola D, Spagnolo A, Guaza C, et al. Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice. Exp Neurol. 2010;222(2):235–242.
   PubMed Web of Science ®Google Scholar
• Rentzos M, Cambouri C, Rombos A, et al. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci. 2006;241(1–2):25–29.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164–174.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188–2197.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(4):1089–1104.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(10):2925–2937.
   PubMed Web of Science ®Google Scholar
• Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(9):2755–2771.
   PubMed Web of Science ®Google Scholar
• Haider L, Zrzavy T, Hametner S, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain. 2016;136:807–815.
   Web of Science ®Google Scholar
• Blauth K, Owens GP, Bennett JL. The ins and outs of B cells in multiple sclerosis. Front Immunol. 2015;6:1–7.
   PubMed Web of Science ®Google Scholar
• Fomby P, Cherlin AJ. Inflammatory cell trafficking across the blood-brain barrier (BBB): chemokine regulation and in vitro models. Immunol Rev. 2012;248(1):228–239.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195–200.
   PubMed Web of Science ®Google Scholar
• Haugen M, Frederiksen JL, Degn M. B cell follicle-like structures in multiple sclerosis—with focus on the role of B cell activating factor. J Neuroimmunol. 2014;273:1–7.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9(1):93.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Columba-Cabezas S, Serafini B. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;148:11–23.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73(23):2003–2010.
   PubMed Web of Science ®Google Scholar
• Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011;17(7):819–829.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One. 2010;5(8):8–13.
   Web of Science ®Google Scholar
• Khademiv M, Kockum I, Andersson ML. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2010;17(3):335–343.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Galli V, Vitetta F, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol. 2015;283(2015):64–69.
   PubMed Web of Science ®Google Scholar
• Serafini B, Severa M, Columba-Cabezas S. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010;69(7):677–693.
   PubMed Web of Science ®Google Scholar
• Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74(14):1127–1135.
   PubMed Web of Science ®Google Scholar
• Peferoen LAN, Lamers F, Lodder LNR, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133(5):e137.
   PubMedGoogle Scholar
• Lovato L, Willis SN, Rodig SJ, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(2):534–541.
   PubMed Web of Science ®Google Scholar
• Von Büdingen H-C, Tc K, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012;122(12):24–28.
   Web of Science ®Google Scholar
• Beers SA, Chan CHT, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47:107–114.
   PubMed Web of Science ®Google Scholar
• Tipton TR, Roghanian A, Oldham RJ, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015;125(12):1901–1909.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676–690.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. mABs. 2015;7(2):303–310.
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer M, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181(1):822–832.
   PubMed Web of Science ®Google Scholar
• Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, et al. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Jt Bone Spine. 2009;76(5):458–463.
   PubMed Web of Science ®Google Scholar
• vanMeerten T, Hagenbeek A. CD20-Targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47(2):199–210.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Ghesquières H, Larrabee BR, Haioun C, et al. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemo therapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol oncol 2010. doi:10.1002/hon.2305. [Epub ahead of print].
   Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Official information about of indications and usage of rituximab by FDA. Label approved on dec 2014. Retrieved oct 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf
   Google Scholar
• Artron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIII a gene. Blood. 2002;99(3):754–758.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989–995.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Functional FCGR3A 158 V/F and IL-6-174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2014;34(10):1409–1415.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Matsunaga Y, Uchiyama Y, et al. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others. Cancer Med. 2013;2(2):130–143.
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;22:4393–4402.
   Web of Science ®Google Scholar
• De Jong RN, Beurskens FJ, Verploegen S, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14(1):e1002344.
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schifer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33.
   PubMed Web of Science ®Google Scholar
• Zhang B. Ofatumumab. mAbs. 2009;1(4):326–331.
   PubMed Web of Science ®Google Scholar
• Kalaycio ME, George Negrea O, Allen SL, et al. Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(4):803–811.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Ayello J, Van de Ven C, et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015;171(5):763–775.
   PubMed Web of Science ®Google Scholar
• Gabellier L, Cartron G. Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas. TherAdvHematol. 2016 Apr;7(2):85–93.
   Google Scholar
• Leonard JP, Gregory SA, Smith H, et al. CHOP chemotherapy followed by tositumomab and iodine-131 tositumomab for previously untreated diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16(4):191–196.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing- remitting multiple sclerosis: a 72-week, open-label, phase i trial. Ann Neurol. 2008;63:395–400.
   PubMed Web of Science ®Google Scholar
• Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005;62(2):258–264.
   PubMedGoogle Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicentre trial. Ann Neurol. 2009;66(4):460–471.
   PubMed Web of Science ®Google Scholar
• Quan C, ZhangBao J, Lu J, et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol. 2015;282:45–53.
   PubMed Web of Science ®Google Scholar
• Maurer MA, Rakocevic G, Leung CS, et al. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest. 2012;122:1393–1402.
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Bendaoud B, et al. B-cell depletion and repopulation in autoimmune diseases. Clinic Rev Allerg Immunol. 2008;34:50–55.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044–3056.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580–586.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–477.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62–74.
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70.
   PubMed Web of Science ®Google Scholar
• Martin MP, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol. 2009;66(8):1016–1020.
   PubMedGoogle Scholar
• Naismith RT, Piccio L, Lyons J, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis. Neurology. 2010;74(23):1860–1867.
   PubMed Web of Science ®Google Scholar
• Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15:189–192.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–468.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Kinzel S, Feldmann L, et al. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Ann ClinTransl Neurol. 2014;1(7):490–496.
   PubMed Web of Science ®Google Scholar
• Svenningsson A, Bergman J, Dring A, et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm. 2015;2;e79.
   Google Scholar
• Gredler V, Mader S, Schanda K, et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J Neurol Sci. 2013;328:77–82.
   PubMed Web of Science ®Google Scholar
• Lavie F, Micelli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700–702.
   PubMed Web of Science ®Google Scholar
• Topping J, Dobson R, Lapin S, et al. The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult Scler Relat Disord. 2016;6:49–53.
   PubMed Web of Science ®Google Scholar
• De Flon P, Gunnarsson M, Laurell K, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87:141–147.
   PubMed Web of Science ®Google Scholar
• Tony H-P, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13(3):R75.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–1164.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22(10):842–849.
   PubMed Web of Science ®Google Scholar
• Lutt JR, Pisculli ML, Weinblatt ME, et al. Severe non tuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol. 2008;35(8):1683–1685.
   PubMed Web of Science ®Google Scholar
• Komori M, Lin YC, Cortese I, et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann ClinTransl Neurol. 2016;3(3):166–179.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis:Week 144 results of a Phase II, randomised, multicentre trial. Poster 362 presented at the American Academy of Neurology (AAN) 65th Annual Meeting 2013. Retrieved from http://www.medscape.com/viewarticle/781671 and http://www.adelphigroup.com/acl/11-10-12/poster1.pdf
   Google Scholar
• Fyfe I. Ocrelizumab excites ECTRIMS. Nat Rev Neurol. Advance online publication 3 Nov 2015. doi:10.1038/nrneurol.2015.210
   Google Scholar
• Hauser SL, Comi GC, Hartung H-P, et al. Efficacy and Safety of Ocrelizumab in Relapsing Multiple Sclerosis. Results of the Phase III Double-blind, Interferon beta-1a-controlled OPERA I and II Studies. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2015. Platform presentation number 190. Retrieved from http://www.roche.com/dam/jcr:819946d8-6c14-45e1-81f4-bfd438816321/en/irp151012.pdf
   Google Scholar
• Montalban X, Hemmer B, Rammohan K et al. A randomized, double-blind, parallel-group, placebo-controlled phase iii trial to evaluate efficacy and safety of ocrelizumab in primary progressive multiple sclerosis. Poster P.023. Presented at the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016; 2016 Feb 18–20; New Orleans, LA.
   Google Scholar
• Sorensen PS, Kavanagh ST, Austin DJ et al. Follow-up data from the mirror study: a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis. Poster 048 Presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting (MS Boston 2014); 2014 Sep 10–13;
   Google Scholar